Pictlisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor. A related commentary discusses the novel treatment approach of PI3K inhibition, that this pharmacological activity may have an important role in subcategories of luminal breast cancers, but that better understanding of molecular mechanisms of hormone resistance and better selection of patients than at present are required.